GlassScriptPhysician profile
Cynthia Miller
NPI 1437245669
$3,078.43
in general payments reported to CMS, 2019-2025
17 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $983 · 2020: $757 · 2021: $609 · 2022: $495 · 2023: $92.57 · 2024: $38.37 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $234.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $2,421.37 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $123.14 | 2022-2025 | Ingrezza |
| Astrazeneca Pharmaceuticals LP | $68.58 | 2019-2021 | |
| Mylan Specialty L.P. | $59.27 | 2019 | |
| Avanir Pharmaceuticals, INC. | $53.91 | 2021 | |
| Ucb, INC. | $46.72 | 2025 | Nayzilam |
| Sun Pharmaceutical Industries INC. | $43.83 | 2021 | |
| Philips North America LLC | $43.79 | 2019 | |
| Sumitomo Pharma America, INC. | $40.10 | 2023 | Gemtesa, Aptiom |
| Otsuka America Pharmaceutical, INC. | $36.35 | 2023-2024 | Rexulti, Nuedexta |
| Fisher & Paykel Healthcare INC | $30.16 | 2022 | |
| Glaxosmithkline, LLC. | $23.62 | 2019 | |
| Optinose US, INC. | $22.12 | 2020 | |
| Astellas Pharma US INC | $20.09 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.43 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $16.35 | 2024 | Austedo Xr |
| Apria Healthcare LLC | $12.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.